UCB

About

You see, UCB wants to be a world leader when it comes to treating ailments related to the immune and central nervous systems (CNS).

Brussels,Brussels Hoofdstedelijk Gewest,Belgium
10001 - max
http://www.ucb.com

Highlights

Details

Last Funding Type: Post-IPO Equity
Last Funding Money Raised: €94.50M
Industries: Biotechnology,Health Care,Pharmaceutical
Founded date: Jan 1, 1928
Number Of Employee: 10001 - max
Operating Status: Active
Stock Symbol: ebr:UCB
Legal Name: UCB S.A.

UCB Pharma operates as a biopharmaceutical company with a focus on neurology and immunology diseases. The company leverages scientific advances and skills in areas such as genetics, biomarkers, and human biology.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

€94.50M $100.78M

UCB has raised a total of €94.50M $100.78M in funding over 2 rounds. Their latest funding was raised on May 24, 2022 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
May 24, 2022	Post-IPO Equity	€94.50M	1	Financière de Tubize SA	—	Detail
May 13, 2015	Post-IPO Equity	$787.62K	—	—	—	Detail
Dec 22, 2009	Post-IPO Equity	$100M	1	Paul Capital	—	Detail
Jan 7, 2000	IPO	—	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

8

2

UCB has made 8 investments. Their most recent investment was on Oct 4, 2022, when Bingli raised €5.40M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Oct 4, 2022 Bingli	Series A	€5.40M	Apps	—
Jan 13, 2021 Nile AI	Corporate Round	€25M	Artificial Intelligence	Yes
Feb 5, 2019 Aetion	Series B	$27M	Analytics	—
Sep 25, 2018 Ceribell	Series B	$35M	Biotechnology	—
Jun 13, 2018 StrideBio	Series A	$15.70M	Biotechnology	—

Investors

Number of Lead Investors

Number of Investors

2

UCB is funded by 2 investors. Financière de Tubize SA and Paul Capital are the most recent investors.

Investor Name	Lead Investor	Funding Round
Financière de Tubize SA	Yes	Post-IPO Equity
Paul Capital	Yes	Post-IPO Equity

Employee Profiles

Number of Employee Profiles

55

UCB has 55 current employee profiles, including Employee Geert Behets

Employee

Executive

Employee

Employee

Executive

Exits

UCB has had 3 exits. UCB most notable exits include Clementia Pharmaceuticals , Dermira

Date	Company Name	Exit Type	Industry
Aug 22, 2017	Clementia Pharmaceuticals	M&A	Biopharma	Detail
Oct 3, 2014	Dermira	M&A	Biopharma	Detail
Jan 11, 2011	Synosia Therapeutics	M&A	Biotechnology	Detail

Acquisition

UCB has acquired 10 organizations. Their most recent acquisition was Celltech Therapeutics on May 18, 2004. They acquired Celltech Therapeutics for 0.

Date Company Name	Industry	Acquisition Type	Price
May 18, 2004 Celltech Therapeutics	Biotechnology	acquisition	—	Detail
Jan 1, 2006 Intranasal Therapeutics	Biotechnology	acquisition	—	Detail
Sep 25, 2006 Schwarz Pharma AG	Medical	acquisition	€ 4.40M	Detail
Nov 22, 2011 Lectus Therapeutics	Biotechnology	acquisition	—	Detail
Jun 6, 2017 Beryllium Discovery	Biotechnology	acquisition	—	Detail